Details of the PSS

General Information of Protein Scaffold of SBP (PSS) (ID: PS028)
PSS Name	DART
Synonyms	Dual affinity re-targeting protein; Dual-affinity Retargeting molecular
Diagrammatic Sketch
Highest Status	Phase III
Class	Antibody fragment
Fold Type	Beta-Sheets + Loops
Thermal Denaturation TEMP	>68℃
Sequence Length	455-552
Molecular Weight	50-60 kDa

Parental Protein of This PSS

Parental Protein Name	Synonym		PDB ID	UniProt ID	Origin
Antibody	N.A.		N.A.	N.A.	Human; Mouse; Synthetic construct

Synthetic Binding Protein (SBP) Featuring this PSS

SBP Name	Highest Status	Template	Expression System	Selection Method	Details	Ref
DART Tebotelimab	Phase III	N.A.	N.A.	N.A.	SBP Info	[1]
DART Flotetuzumab	Phase II	N.A.	N.A.	N.A.	SBP Info	[2], [3]
DART MGD-010	Phase II	N.A.	N.A.	N.A.	SBP Info	[4]
DART Duvortuxizumab	Phase I; Discontinued	N.A.	N.A.	N.A.	SBP Info	[1]
DART MGD-019	Phase I	N.A.	N.A.	N.A.	SBP Info	[1]
DART Obrindatamab	Phase I; Discontinued	N.A.	N.A.	N.A.	SBP Info	[5]
DART anti-cadherin/CD3 153	Research	N.A.	Human embryonic kidney?cells 293	Phage display	SBP Info	[6]
DART anti-cadherin/CD3 20	Research	N.A.	Human embryonic kidney?cells 293	Phage display	SBP Info	[6]
DART anti-cadherin/CD3 30	Research	N.A.	Human embryonic kidney?cells 293	Phage display	SBP Info	[6]
DART anti-cadherin/CD3 33	Research	N.A.	Human embryonic kidney?cells 293	Phage display	SBP Info	[6]
DART anti-cadherin/CD3 34	Research	N.A.	Human embryonic kidney?cells 293	Phage display	SBP Info	[6]
DART anti-cadherin/CD3 35	Research	N.A.	Human embryonic kidney?cells 293	Phage display	SBP Info	[6]
DART anti-cadherin/CD3 PF-06671008	Research	N.A.	Chinese hamster ovary cells	Phage display	SBP Info	[6]
DART anti-FOLR1 h38C2 x v9	Research	Farletuzumab and v9	Human embryonic kidney?cells 293	N.A.	SBP Info	[7]
DART anti-Beta-diketone/CD3 DART	Research	N.A.	N.A.	N.A.	SBP Info	[7]
DART anti-CD3 MGD015	Research	N.A.	N.A.	N.A.	SBP Info	[8]
DART anti-FOLR1/CD3 DART	Research	N.A.	N.A.	N.A.	SBP Info	[7]
DART anti-GPA33/CD3 MGD007	Research	N.A.	N.A.	N.A.	SBP Info	[1]
DART anti-HIV Env/CD3 MGD014	Research	N.A.	N.A.	N.A.	SBP Info	[1]

References

1	MacroGenics. Product Development Pipeline. 2021.
2	Recent advances in the development of novel protein scaffolds based therapeutics. Int J Biol Macromol. 2017 Sep;102:630-641.
3	KEGG DRUG Database. Flotetuzumab
4	MacroGenics. MacroGenics Presents Updated Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2017). Jun 17 2017.
5	MacroGenics. Data from MacroGenics' Preclinical Studies of MGD009 Presented at Keystone Symposia's Antibodies as Drugs (X2) Conference. Mar 7 2016.
6	Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer. Antibodies (Basel). 2016 Mar 4;5(1):6.
7	Chemically Programmed Bispecific Antibodies in Diabody Format. J Biol Chem. 2016 Sep 9;291(37):19661-73.
8	MacroGenics. MacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD015. Jun 28 2016.